Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II data for verinurad plus febuxostat in patients with gout and asymptomatic hyperuricemia

Dec. 7, 2016

FDA approves new indication for Jardiance

Dec. 5, 2016

Lilly patents novel DGAT-2 inhibitors

Dec. 5, 2016

Amryt Pharma in-licenses European and Middle Eastern rights to Lojuxta

Dec. 5, 2016

Mochida obtains Japanese approval for Dinagest for adenomyosis

Dec. 5, 2016

DiaMedica sells DM-71 and related IP

Dec. 5, 2016

IONIS-ANGPTL3-LRx shows potential to reduce plasma ANGPTL3 and lipids

Dec. 2, 2016

Aequus BioPharma synthesizes melanocortin fusion peptide for treating gout

Dec. 2, 2016

EC grants orphan designation to Agilis Biotherapeutics' AGIL-AADC

Dec. 2, 2016

Ultragenyx Pharmaceutical reports 78-week data from phase II study of UX-007

Dec. 1, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026